ERBB2 and breast carcinoma: The identification of the HER2 (human epidermal growth factor receptor) receptor, its critical role in breast cancer tumorigenesis, and its targeting with monoclonal antibodies have significantly revolutionized the treatment of HER2-positive cancers [37].